On March 30, 2020, the revised Drug Registration Regulation was issued by the State Administration for Marketing Regulation and will be put into effect from July 1, 2020. The revised regulation is focused on the acceleration of clinical trial approval, implementing a risk-based approach in clinical development, protecting trial subjects’ rights, and overall enhancing the in-process administration, from filing, review, and risk-based site inspections till suspension and even termination of clinical trials. Also, we will touch on the liabilities throughout drug lifecycle.

Encouragingly, the revised Drug Registration Regulation has optimized the overall review and approval framework, systems, principles, and procedures. It becomes another important milestone to foster the fast growth of the pharmaceutical industry and to further satisfy the unmet medical needs of the public in China.

This webinar is co-organised by Tigermed and SCCC.

Watch here the webinar recording: